Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B
belimumab is an approved drug (FDA (2011), EMA (2011))
Compound class:
Antibody
Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,4] , an immunostimulant essential for normal B cell maintenance and humoral immunity [5], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases
View more information in the IUPHAR Pharmacology Education Project: belimumab |
References |
1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum, 48 (11): 3253-65. [PMID:14613291] |
2. Dörner T. (2006)
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl, 77: 3-11. [PMID:16652439] |
3. Lutalo PM, D'Cruz DP. (2014)
Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323] |
4. Sabahi R, Anolik JH. (2006)
B-cell-targeted therapy for systemic lupus erythematosus. Drugs, 66 (15): 1933-48. [PMID:17100405] |
5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H et al.. (1999)
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med, 189 (11): 1747-56. [PMID:10359578] |